Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Director/PDMR Shareholding

18 Aug 2022 13:25

RNS Number : 5102W
Belluscura PLC
18 August 2022
Β 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THEΒ UKΒ VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura PLC

("Belluscura" or the "Company" orΒ "Group")

Β 

Director / PDMR Shareholding

Β 

LONDON, U.K.Β ANDΒ PLANO, TX,Β U.S.Β (18 August 2022).Β Belluscura plcΒ (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, confirms that further to the notification on 10 August 2022 in respect of his exercise of options over 690,395 shares, Robert Rauker (CEO) has today transferred 455,064 shares to his ex-wife pursuant to a divorce settlement.

Β 

Following the transfer,Β Mr Rauker'sΒ holding is 1,191,015 shares and his total interest in the Company is 0.97% of the Company's issued share capital.

Β 

Β 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via MHP Communications

Anthony Dyer, Chief Financial Officer

Β 

SPARK Advisory Partners Ltd (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin

Β 

Dowgate Capital Ltd (Broker & Bookrunner)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

Β 

MHP Communications (Media & Investor Relations)

Tel: +44 (0)20 3128 8100

Katie Hunt / Pete Lambie / Matthew TaylorΒ 

or belluscura@mhpc.com

Β 

Β 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.

Β 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Robert Rauker

2

Reason for notification

a)

Position / status

Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

DetailsΒ ofΒ theΒ issuer, emissionΒ allowanceΒ marketΒ participant,Β auctionΒ platform, auctioneerΒ orΒ auctionΒ monitor

a)

Name

Belluscura plc

b)

LEI

213800BRJQZE56XBPW94

4

DetailsΒ ofΒ theΒ transaction(s): sectionΒ toΒ beΒ repeatedΒ forΒ (i)Β eachΒ typeΒ ofΒ instrument;Β (ii)Β eachΒ typeΒ ofΒ transaction;Β (iii)Β eachΒ date;Β andΒ (iv)Β eachΒ placeΒ whereΒ transactionsΒ haveΒ beenΒ conducted

a)

DescriptionΒ ofΒ theΒ financial instrument,Β type ofΒ instrument

IdentificationΒ code

Β 

Ordinary shares of Β£0.01 each in Belluscura plc

ISINΒ : GB00BD3B8Z11

b)

Nature of the transaction

(i) Transfer of shares

c)

Price(s) and volumes(s)

Β 

Price(s)

Volumes(s)

n/a

455,064

d)

Aggregated information

n/a

e)

Date of the transaction

17 August 2022

f)

Place of the transaction

Outside a trading venue

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHPPMTTMTBBBFT
Date   Source Headline
13th Jan 202211:05 amRNSSecond Price Monitoring Extn
13th Jan 202211:00 amRNSPrice Monitoring Extension
7th Dec 20217:00 amRNSExercise of Warrants and Total Voting Rights
29th Nov 20217:01 amRNSReimbursement approvals
29th Nov 20217:00 amRNSExercise of Warrants and Total Voting Rights
4th Nov 20217:00 amRNSTrading update
1st Nov 20217:00 amRNSThe Pulse: Healthcare Innovation Breakfast
25th Oct 20217:00 amRNSProduct wins Top Award at US Trade show
18th Oct 20217:00 amRNSNew US Distribution Agreement
8th Oct 20217:00 amRNSDirector/PDMR Shareholding
2nd Sep 20217:00 amRNSNotice of Results
31st Aug 20217:00 amRNSBelluscura supports rationale for wider oxygen use
27th Jul 20217:00 amRNSManufacturing and Distribution Agreement
13th Jul 20217:00 amRNSThird US Distribution Agreement
8th Jul 20217:00 amRNSThe US Centers for Medicare & Medicaid Services
5th Jul 20217:00 amRNSSecond US Distribution Agreement
30th Jun 202112:29 pmRNSResult of AGM
24th Jun 20211:13 pmRNSHolding(s) in Company
23rd Jun 20214:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20214:36 pmRNSPrice Monitoring Extension
23rd Jun 20212:05 pmRNSSecond Price Monitoring Extn
23rd Jun 20212:00 pmRNSPrice Monitoring Extension
23rd Jun 20217:00 amRNSFirst US Distribution Agreement
15th Jun 20217:00 amRNSSenior Management Appointment
9th Jun 20214:15 pmRNSExercise of Warrants
2nd Jun 20217:00 amRNSHolding(s) in Company
28th May 20217:00 amRNSAdmission to trading on AIM; First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.